Anna Richo is an attorney who has rendered her services as a counsel to several healthcare and medical companies including UCB, where she is also an executive vice president. Anna Richo was previously the senior vice president and chief compliance officer at Amgen, Inc. Both of the abovementioned companies figured in a press release by Amgen earlier this year as they announced the positive results of a phase 3 study which aimed to evaluate the effects of Romosozumab on men with Osteoporosis. The 3rd phase study, named placebo-controlled study evaluatIng the efficacy and safety of Romosozumab in treating men with osteoporosis, yielded data showing that the drug met the primary endpoint and actually demonstrated a significant increase in bone mineral density (BMD) among men with osteoporosis. The data were confirmed using a dual energy x-ray absorptiometry. The secondary endpoints of the study were also met. Those who received Romosozumab showed significant increases in BMD at the femoral neck and total hip within a year. Moreover, results started showing as early as six months with a significant increase of BMD at the lumbar spine, femoral neck, and total hip compared to those who were on placebo.
0 Comments
|
AuthorAs of November 1, 2012, Anna Richo became Executive Vice President and General Counsel of UCB, a biopharmaceutical company headquartered in Brussels, Belgium. Archives
August 2018
Categories
All
|